UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): April 15, 2009
|
DELCATH
SYSTEMS, INC.
|
|
(Exact
Name of Registrant as Specified in
Charter)
|
|
DELAWARE
|
001-16133
|
06-1245881
|
||
|
(State
of Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
600
FIFTH AVENUE, 23rd
FLOOR
NEW
YORK, NEW YORK
|
10020
|
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code: (212) 489-2100
Check the
appropriate box below if the Form 8−K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a−12 under the Exchange Act (17 CFR
240.14a−12)
[ ]
Pre−commencement communications pursuant to Rule 14d−2(b) under the Exchange Act
(17 CFR
240.14d−2(b))
[ ]
Pre−commencement communications pursuant to Rule 13e−4(c) under the Exchange Act
(17 CFR 240.13e−4(c))
Item
7.01 Regulation
FD Disclosure.
On April
15, 2009, Delcath Systems, Inc. issued a press release announcing a quarterly
update conference call and access thereto. A copy of the press release is
attached hereto as Exhibit 99.1.
The
information contained in Item 7.01 of this Report and the exhibit attached
hereto shall not be deemed “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to
the liabilities of that section, and shall not be incorporated by reference into
any registration statement or other document filed under the Securities Act of
1933 or the Exchange Act.
Item
9.01 Financial
Statements and Exhibits.
(d) Exhibits
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
Release of Delcath Systems, Inc., dated April 15,
2009
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
Date: April
17, 2009
| DELCATH SYSTEMS, INC. | |||
|
|
By:
|
/s/ Richard L. Taney | |
| Name: Richard L. Taney | |||
| Title: Chief Executive Officer | |||
EXHIBIT
99.1
Delcath
Systems to Host Quarterly Update Conference Call
NEW YORK,
NY, April 15, 2009 – Delcath Systems, Inc. (NASDAQ: DCTH) will host its
quarterly update conference call at 4:30 PM Eastern Time on Wednesday, April 22,
2009. Richard Taney, President and Chief Executive Officer of Delcath Systems,
will host the call.
To
participate in the call, interested parties may dial (888) 790-3326
(U.S./Canada) and use Conference Password: Delcath. The call will be
archived and made available shortly after the call on the Company’s website,
www.delcath.com.
About
Delcath Systems, Inc.
Delcath
Systems, Inc. is a medical technology company specializing in cancer treatment.
The Company is testing a proprietary, patented drug delivery system for the
treatment of liver cancers. Delcath's novel drug delivery platform is testing
the delivery of ultra-high doses of anti-cancer drugs to the liver while
preventing these high doses of drug from entering the patient's bloodstream. The
Company is currently enrolling patients in Phase III and Phase II clinical
studies for the treatment of liver cancers using high doses of melphalan. The
Company's intellectual property portfolio consists of twenty-seven patents on a
worldwide basis including the U.S., Europe, Asia and Canada. For more
information, please visit the Company's website at www.delcath.com.
The
Private Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf. This
news release contains forward-looking statements, which are subject to certain
risks and uncertainties that can cause actual results to differ materially from
those described. Factors that may cause such differences include, but are not
limited to, uncertainties relating to our ability to successfully complete Phase
III clinical trials and secure regulatory approval of our current or future
drug-delivery system and uncertainties regarding our ability to obtain financial
and other resources for any research, development and commercialization
activities. These factors, and others, are discussed from time to time in our
filings with the Securities and Exchange Commission. You should not place undue
reliance on these forward-looking statements, which speak only as of the date
they are made. We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the date
they are made.
# # #
Company
Contact:
Delcath
Systems, Inc.
Richard
Taney
(212)
489-2100
info@delcath.com
Public Relations
Contact:
Rubenstein
Associates, Inc.
Robin
Wagge
(212)
843-8006
rwagge@rubenstein.com